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BDP/FF MART regimen reduced the incidence of severe asthma exacerbations compared 
with BDP/FF maintenance therapy plus salbutamol as needed across the blood eosinophil 
continuum, with a trend to a greater reduction in patients with higher baseline counts.  
To the editor, 
A number of studies have evaluated the effectiveness of a ‘Maintenance And Reliever 
Therapy’ (MART) regimen combining in a single inhaler the rapid-acting, long-acting β2-
agonist (LABA) formoterol fumarate (FF) with an inhaled corticosteroid (ICS) in asthma [1–
5]. Such a regimen is now established for the treatment of moderate-to-severe asthma in 
adolescents and adults in many guidelines [6, 7]. Furthermore, rescue short-acting β2-
agonists (SABAs) are no longer recommended as sole therapy even for patients with mild 
asthma, and an ICS/FF combination used as needed is the preferred reliever therapy [6].  
A number of studies have examined the impact of a MART regimen on markers of airway 
inflammation, with discordant findings: In a substudy conducted by Sears et al. a MART 
regimen had a similar impact on the change from baseline in sputum eosinophil levels to 
conventional best practice [8], whereas in a study by Pavord et al. MART was less effective 
in reducing sputum eosinophil levels than high-dose ICS/LABA maintenance treatment, 
resulting in a significant difference between groups [9]. In contrast in a study by Hozawa et 
al. a MART regimen was more effective than maintenance ICS/LABA in suppressing airways 
inflammation [10]. However, these studies did not evaluate the correlation between baseline 
inflammatory marker levels and the relative efficacy of a MART regimen on clinical outcomes 
in general, and asthma exacerbations in particular. 
Here we therefore investigate whether, in patients with moderate-to-severe asthma, blood 
eosinophils are theragnostic biomarkers for the relative efficacy of an ICS/FF MART regimen 
versus maintenance ICS/FF plus rescue SABA. To this aim we performed post-hoc analyses 
of a randomised controlled trial in patients with uncontrolled asthma, who had been receiving 
ICS (with or without LABA) for at least two months prior to study entry [3]. The study was 48 
weeks in duration, and recruited 1714 adults with asthma who had at least one severe 
asthma exacerbation in the previous 12 months, pre-bronchodilator forced expiratory volume 
in 1 second (FEV1) ≥60% predicted, and whose asthma had been treated regularly with ICS 
(beclometasone equivalent ≥1000 μg/day) or ICS (beclometasone equivalent ≥500 μg/day) 
plus LABA for the previous two months [3]. All patients received maintenance treatment with 
extrafine beclometasone dipropionate (BDP) 100 μg plus FF 6 μg, one inhalation twice daily 
via pressurised metered dose inhaler (pMDI), for the duration of the study, including a two-
week run-in period. At the end of the run-in period patients whose asthma was not fully 
controlled (at least one of the following: use of rescue medication more than twice a week; 
any limitation of activities; any nocturnal symptoms or awakenings; daytime symptoms more 
than twice a week; or FEV1 <80% predicted) were randomised equally (1:1) to use as rescue 
medication either the same extrafine BDP/FF pMDI (i.e., MART regimen) or salbutamol (the 
BDP/FF+salbutamol group), both one inhalation as needed up to a maximum of six extra 
inhalations per day. The occurrence of a severe exacerbation was defined as an asthma 
deterioration resulting in admission to hospital or an emergency department visit, or requiring 
systemic steroids for at least three days. All patients provided written informed consent prior 
to any study-related procedure, and the study was registered with ClinicalTrials.gov 
(NCT00861926). In the overall analyses, the MART regimen significantly increased the time 
to first severe asthma exacerbation compared with the BDP/FF+salbutamol group, with a 
34% reduction in the annualised rate of severe exacerbations (p<0.0001) [3]. For the current 
post-hoc analyses, the annualised rate of severe exacerbations was compared between the 
two treatment groups by using a Poisson regression model with number of severe asthma 
exacerbations as dependent variable, treatment, and country as factors, and with log-time on 
study as offset. We conducted two sets of analyses. First, patients were grouped by baseline 
blood eosinophil count into three categories: <150, 150–300 and >300 cells/µL (assessed at 
the end of the two-week run-in period). The second set of analyses was performed across 
the blood eosinophil continuum.  
When analysed by blood eosinophil category, in the BDP/FF+salbutamol group the 
percentage of patients with at least one severe exacerbation and the rate of severe 
exacerbations were both highest in patients with eosinophils >300 cells/µL, but were similar 
in the other two eosinophil categories (Figure 1a and b). In contrast, in patients receiving the 
MART regimen, severe exacerbation percentages and rates were similar in all three 
eosinophil categories, such that the risk reduction versus BDP/FF+salbutamol was greatest 
in the >300 cells/µL category (a significant 45.9% risk reduction: rate ratio 0.541 [95% CI 
0.397, 0.738]; p<0.001), followed by the 150–300 cells/µL category (a significant 29.5% risk 
reduction; 0.705 [0.506, 0.983]; p=0.039), although when tested for an interaction between 
eosinophil count and treatment, the p value was not significant (p=0.191). When analysed 
across the blood eosinophil continuum, as with the categorical analysis, there was a trend to 
increasing severe exacerbation rate with increasing eosinophil counts in the 
BDP/FF+salbutamol group, whereas with the MART regimen the rates were similar 
regardless of eosinophil count (Figure 1c). Consequently, there was a trend to increasing 
efficacy with increasing eosinophil levels, although the MART regimen had a greater effect 
on exacerbations than the BDP/FF+salbutamol group across the entire blood eosinophil 
continuum (Figure 1d). When the interaction between eosinophil count and treatment was 
tested across the full continuum (therefore using all information from the data), this 
approached statistical significance (p=0.083) despite the study being underpowered for this 
type of analysis. Use of rescue medication was similar in the two treatment groups 
regardless of eosinophil category (adjusted mean reductions from baseline in reliever use at 
Week 47–48 of: eosinophils <150 cells/µl, 0.29 and 0.30 inhalations per day; 150–300 
cells/µL, 0.25 and 0.25 inhalations per day; >300 cells/µL, 0.31 and 0.25 inhalations per day 
with the MART regimen and BDP/FF+salbutamol, respectively). 
The results for the BDP/FF MART regimen in our study are consistent with those of a 
previous post-hoc analysis of the NovelSTART study, which recruited patients who had been 
using SABA as sole therapy for asthma, and randomised them to continue salbutamol alone 
as needed, to receive budesonide/FF (BUD/FF) as needed, or to receive BUD maintenance 
therapy plus salbutamol as needed [11]. In that post-hoc analysis, patients were grouped by 
screening blood eosinophil counts in similar categories to those we used (<150, 150–<300 
and ≥300 cells/µL): For the group receiving BUD/FF as needed  the incidence of severe 
exacerbations was similar across blood eosinophil categories [12]. Furthermore, the relative 
benefit of ICS-based rescue therapy in the two studies (i.e., BDP/FF MART regimen vs 
BDP/FF+salbutamol in our analyses and BUD/FF as needed vs salbutamol as needed in 
NovelSTART) increased with increasing blood eosinophil category. The two studies together 
thus emphasise the importance of ICS-based rescue therapy regardless of background 
therapy. 
Overall, therefore, BDP/FF MART reduced the incidence of severe asthma exacerbations 
compared with BDP/FF maintenance therapy plus salbutamol as needed across the blood 
eosinophil continuum and there was a trend to greater reduction of severe exacerbations in 
patients with higher baseline eosinophil counts.  
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Figure legend 
Figure 1. Severe asthma exacerbations: a) Percentage of patients with at least one 
exacerbation by baseline blood eosinophil category; b) Mean annualised rate and treatment 
contrasts by baseline blood eosinophil category; c) Mean annualised rate and treatment 
contrasts across baseline blood eosinophil continuum; d) Adjusted severe exacerbation rate 
ratio BDP/FF MART regimen vs BDP/FF maintenance plus salbutamol as needed across 
baseline eosinophil continuum. 
BDP, beclometasone dipropionate; FF, formoterol fumarate; MART, Maintenance And Reliever Therapy; RR, risk reduction. 
 
